Immunosenescence In Elderly Patients With Advanced Non-Small Cell Lung Cancer: Mechanisms And Therapeutic Implications
As we age, our immune system naturally undergoes a decline in function, a process called immunosenescence. This isn’t just about getting sick more often; it has significant implications for how our bodies fight diseases like cancer. In older adults with a common type of lung cancer, non-small cell lung cancer (NSCLC), this age-related immune decline plays a crucial role in how the disease develops, progresses, and responds to treatment.
Immunosenescence involves various changes in our immune cells. For instance, the thymus gland, which produces important immune cells called T-cells, shrinks over time (thymic involution). T-cells can also become “exhausted,” meaning they lose their ability to effectively fight off threats. Other changes include alterations in gene activity without changing the DNA sequence (epigenetic modifications) and a persistent, low-level inflammation throughout the body.
These changes weaken the body’s ability to detect and eliminate cancer cells, a process known as tumor immune surveillance. They also affect the tumor microenvironment, which is the complex network of cells and molecules surrounding a tumor. Ultimately, immunosenescence can make current cancer treatments, especially immunotherapies that rely on a strong immune response, less effective in elderly patients.
Understanding these mechanisms is vital for developing new strategies. By targeting the processes of immunosenescence, researchers hope to create more effective treatments that can slow cancer progression and improve the success of immunotherapies, ultimately leading to better outcomes for older patients with NSCLC.
Source: link to paper